Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00150319 · ClinicalTrials.gov registry record · Phase 1
An Open-Label Study To Assess The Pharmacokinetics, Safety And Toleration Of Vfend®; Following Multiple Dosing With Vfend
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT00150319 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 1 participants.
The verdict
NCT00150319, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a study to investigate the pharmacokinetics, safety and tolerability of intravenous voriconazole and SBECD in patients with moderate renal insufficiency
Interventions
- DRUG Vfend®; I.V.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2005-06 |
| Est. Completion | 2005-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00150319
The ClinicalTrials.gov registry entry for NCT00150319 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vfend®; I.V. is the first listed.
NCT00150319 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00150319 about?
NCT00150319 is a clinical study titled "An Open-Label Study To Assess The Pharmacokinetics, Safety And Toleration Of Vfend®; Following Multiple Dosing With Vfend". This is a study to investigate the pharmacokinetics, safety and tolerability of intravenous voriconazole and SBECD in patients with moderate renal insufficiency
What is the current status of trial NCT00150319?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2005-06. Estimated completion is 2005-10.
What interventions are being tested in trial NCT00150319?
The interventions under investigation include: Vfend®; I.V. (DRUG).
Who is sponsoring clinical trial NCT00150319?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.